Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (181-190 of 539) with videos related to

Pageof 54
Sort By:
JCO Precision Oncology|July 10, 2024
Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell TransplantationManuela Hummel, Thomas Hielscher, Martina Emde-Rajaratnam, et al.
BMC Medical Genomics|December 31, 2015
Profound impact of sample processing delay on gene expression of multiple myeloma plasma cellsTobias Meißner, Anja Seckinger, Kari Hemminki, et al.
Cancers|September 28, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple MyelomaMarc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, et al.
Haematologica|November 22, 2011
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myelomaAlboukadel Kassambara, Dirk Hose, Jérôme Moreaux, et al.
European Journal of Heart Failure|March 14, 2007
Non-invasive predictors of survival in cardiac amyloidosisArnt V Kristen, Jolanta B Perz, Stefan O Schonland, et al.
NPJ Digital Medicine|April 30, 2025
Predicting progression events in multiple myeloma from routine blood workMaximilian Ferle, Nora Grieb, Markus Kreuz, et al.
Oncotarget|October 17, 2015
miRNAs in multiple myeloma--a survival relevant complex regulator of gene expressionAnja Seckinger, Tobias Meißner, Jérôme Moreaux, et al.
Leukemia & Lymphoma|November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparisonMaria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
British Journal of Haematology|August 25, 2021
Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after up-front autologous transplantationElias K Mai, Thomas Schmitt, Aleksandar Radujkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimensTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Pageof 54

Showing results (181-190 of 539) with videos related to

Sort By:
Pageof 54
JCO Precision Oncology|July 10, 2024
Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell TransplantationManuela Hummel, Thomas Hielscher, Martina Emde-Rajaratnam, et al.
BMC Medical Genomics|December 31, 2015
Profound impact of sample processing delay on gene expression of multiple myeloma plasma cellsTobias Meißner, Anja Seckinger, Kari Hemminki, et al.
Cancers|September 28, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple MyelomaMarc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, et al.
Haematologica|November 22, 2011
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myelomaAlboukadel Kassambara, Dirk Hose, Jérôme Moreaux, et al.
European Journal of Heart Failure|March 14, 2007
Non-invasive predictors of survival in cardiac amyloidosisArnt V Kristen, Jolanta B Perz, Stefan O Schonland, et al.
NPJ Digital Medicine|April 30, 2025
Predicting progression events in multiple myeloma from routine blood workMaximilian Ferle, Nora Grieb, Markus Kreuz, et al.
Oncotarget|October 17, 2015
miRNAs in multiple myeloma--a survival relevant complex regulator of gene expressionAnja Seckinger, Tobias Meißner, Jérôme Moreaux, et al.
Leukemia & Lymphoma|November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparisonMaria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
British Journal of Haematology|August 25, 2021
Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after up-front autologous transplantationElias K Mai, Thomas Schmitt, Aleksandar Radujkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimensTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Pageof 54